Literature DB >> 357967

Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (first of three parts).

J Dean, A N Schechter.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 357967     DOI: 10.1056/NEJM197810052991405

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  26 in total

1.  Proceedings of the British Pharmacological Society. Leeds, 12th-14th July 1989. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

2.  13C NMR quantitation of polymer in deoxyhemoglobin S gels.

Authors:  C T Noguchi; D A Torchia; A N Schechter
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

3.  Visualization of oriented hemoglobin S in individual erythrocytes by differential extinction of polarized light.

Authors:  W Mickols; M F Maestre; I Tinoco; S H Embury
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

4.  Sickle erythrocyte adherence to vascular endothelium. Morphologic correlates and the requirement for divalent cations and collagen-binding plasma proteins.

Authors:  N Mohandas; E Evans
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

Review 5.  Management of sickle cell disease.

Authors:  M Brozović; S Davies
Journal:  Postgrad Med J       Date:  1987-08       Impact factor: 2.401

6.  Proton longitudinal relaxation investigation of histidyl residues of normal human adult and sickle deoxyhemoglobin: evidence for the existence of pregelation aggregates in sickle deoxyhemoglobin solutions.

Authors:  I M Russu; C Ho
Journal:  Proc Natl Acad Sci U S A       Date:  1980-11       Impact factor: 11.205

7.  Pharmacokinetics and pharmacodynamics of tucaresol, an antisickling agent, in healthy volunteers.

Authors:  P E Rolan; A J Mercer; R Wootton; J Posner
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

8.  The pharmacokinetics, tolerability and pharmacodynamics of tucaresol (589C80; 4[2-formyl-3-hydroxyphenoxymethyl] benzoic acid), a potential anti-sickling agent, following oral administration to healthy subjects.

Authors:  P E Rolan; J E Parker; S J Gray; B C Weatherley; J Ingram; W Leavens; R Wootton; J Posner
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

9.  Shape change of sickled erythrocytes induced by pulsed rf electrical fields.

Authors:  S Takashima; S Chang; T Asakura
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

10.  Characterization of the binding of the anti-sickling compound, BW12C, to haemoglobin.

Authors:  M Merrett; D K Stammers; R D White; R Wootton; G Kneen
Journal:  Biochem J       Date:  1986-10-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.